New Bispecific Shrinks NRG1 Fusion-Positive Lung, Pancreatic Tumors

(MedPage Today) -- Zenocutuzumab (Bizengri), a bispecific antibody against HER2 and HER3, showed efficacy in patients with advanced NRG1 fusion-positive cancers, particularly non-small cell lung cancer (NSCLC) and pancreatic cancer, according to...